Parkinson’s disease, a progressive disorder characterized predominantly by the death of dopaminergic neurons in the substantia nigra, leads to a debilitating reduction in dopamine levels. This neurotransmitter is crucial for regulating motor control, motivation, and reward, and its deficiency manifests as hallmark symptoms such as tremors, rigidity, and bradykinesia. Traditionally, treatments have focused mainly on symptomatic relief through dopamine replacement therapies, notably levodopa, which, despite its efficacy in early stages, encounters diminishing returns due to long-term complications.

The UNIFESP researchers have shifted the focus toward the underlying neuroinflammatory processes that exacerbate neuronal death. Annexin A1, a protein intrinsically involved in resolving inflammation, has been shown to be altered in Parkinsonian brains, signifying its potential role in disease progression. Their innovative approach leverages the Ac2-26 peptide, an N-terminal fragment of Annexin A1, known for its potent anti-inflammatory properties. Previous animal studies had suggested the peptide’s capacity to modulate neuroinflammation, but UNIFESP’s investigation is among the first to elucidate its precise effects on dopaminergic neuron preservation in Parkinson’s models.

In their experiments, the team employed a neurotoxin, 6-hydroxydopamine (6-OHDA), to entrench a Parkinson-like state in mice by inducing selective dopaminergic neuron degeneration. Simultaneously administering Ac2-26 intraperitoneally, they observed a significant preservation of these critical neurons, as confirmed via immunofluorescence imaging which highlighted the dopaminergic neurons’ survival post-treatment. This neuroprotection appears to stem from the peptide’s ability to mitigate the inflammatory microenvironment within the brain, an environment often hostile to neuronal longevity in Parkinson’s disease.

What makes this research particularly compelling is the study’s emphasis on neuroinflammation as a target distinct from dopamine replacement. According to Cristiane Damas Gil, the lead investigator and head of the Department of Morphology and Genetics at UNIFESP’s São Paulo School of Medicine, targeting the inflammatory cascade offers a strategy to preserve neuronal architecture and function prior to irreversible degeneration. This contrasts with levodopa’s approach which primarily substitutes dopamine without addressing inflammatory mediators that drive ongoing neuronal damage.

Furthermore, the research highlights intriguing sex differences in disease progression. Female mice initially demonstrated greater resilience against neurodegeneration and better motor performance following 6-OHDA administration, a phenomenon observed even in genetically modified mice lacking Annexin A1. This points to complex biological factors underpinning Parkinson’s pathology and underscores the necessity for sex-specific therapeutic regimens, especially given that the peptide’s protective mechanisms may interface differently with male and female physiology.

Beyond neuroprotection, the study uncovered an unsettling impact of Parkinson’s-like injury on female reproductive cycles, shedding light on the neuroendocrine disruptions associated with Parkinson’s disease. Such findings suggest that the disease’s reach extends beyond motor symptoms, influencing systemic physiological processes, thereby prompting calls for more comprehensive clinical evaluation and tailored treatment interventions.

Luiz Philipe de Souza Ferreira, the principal researcher supported by a FAPESP scholarship, stresses the need for alternative interventions. While levodopa remains the clinical standard due to its symptomatic benefits, it often loses efficacy over time and can engender motor complications like dyskinesias. Therefore, therapies like Ac2-26 that intervene early in the disease’s pathogenesis by curbing inflammation could complement or eventually supplant dopamine-based treatments.

The Ac2-26 peptide has established anti-inflammatory roles in other disease contexts but has yet to progress to clinical pharmaceutical development. Its application in Parkinson’s models constitutes a frontier for translational neuroscience. This peptide’s intervention at the nascent phase of neuronal injury opens the possibility for disease-modifying therapies that could slow or halt the relentless progression currently characteristic of Parkinson’s.

Looking toward the future, the research team is keen to investigate whether Ac2-26’s benefits extend beyond prevention to actively reversing existing neuronal damage. Achieving such a breakthrough could dramatically alter the therapeutic landscape, transforming Parkinson’s from an inevitably progressive disease to a manageable chronic condition, or potentially one with regenerative treatment options.

The implications of this work extend across the fields of neuropharmacology, neurobiology, and clinical neurology. It paves a pathway toward nuanced targeting of neuroinflammation, which has been increasingly recognized as a critical axis in neurodegeneration. Leveraging endogenous proteins and their fragments that naturally orchestrate inflammatory resolution could herald a new class of neuroprotective agents with high specificity and minimal side effects.

These findings, supported by the São Paulo Research Foundation (FAPESP), reflect the burgeoning capacity of Brazilian science to contribute significantly to global neurodegenerative disease research. As the field intensifies its search for mechanistic-based therapies, molecules like Ac2-26 offer tangible hope for patients suffering from Parkinson’s disease, potentially reshaping the future of treatment and improving quality of life for millions worldwide.

Subject of Research: Parkinson’s disease neurodegeneration and neuroinflammation targeting through the Ac2-26 peptide derived from Annexin A1.

Article Title: Annexin A1 and its N-terminal peptide Ac2-26 regulate dopaminergic degeneration and neuroinflammation in a 6-OHDA model of Parkinson’s disease

News Publication Date: 23-Mar-2026

Web References:
https://sciencedirect.com/science/article/pii/S0028390826001152

References:
Ferreira, L.P. de S., Gil, C.D., et al. (2026). Annexin A1 and its N-terminal peptide Ac2-26 regulate dopaminergic degeneration and neuroinflammation in a 6-OHDA model of Parkinson’s disease. Neuropharmacology. DOI: 10.1016/j.neuropharm.2026.110942

Image Credits: Luiz Philipe de Souza Ferreira et al./Neuropharmacology

Keywords

Parkinson’s disease, neuroinflammation, dopaminergic neurons, Ac2-26 peptide, Annexin A1, neuroprotection, 6-OHDA model, levodopa alternatives, neurodegenerative diseases, sex differences in Parkinson’s, endogenous anti-inflammatory agents, neuropharmacology

Parkinson’s disease, characterized primarily by the progressive loss of dopaminergic neurons in the substantia nigra, manifests through motor symptoms such as tremors, rigidity, and bradykinesia, as well as non-motor complications including cognitive decline and autonomic dysfunction. Historically, lifestyle factors like cigarette smoking have been deemed detrimental due to well-established associations with cardiovascular and respiratory diseases. However, epidemiological studies spanning decades have identified an enigmatic inverse correlation between smoking and PD incidence, sparking curiosity about the underlying protective mechanisms.

Contrasting sharply, physical exercise is ubiquitously recognized for its broad health benefits, including enhanced cardiovascular function, neuroplasticity, and metabolic regulation. Exercise has consistently demonstrated protective effects against PD onset and progression, attributed to its ability to modulate inflammation, oxidative stress, and neurotrophic support within the central nervous system. The novelty of the study lies in its comparative approach—scrutinizing exercise and smoking as “health rivals” to elucidate convergent biological effects that could mitigate neurodegeneration.

The multidisciplinary team led by Janssen Daalen et al. employed advanced neurobiological assays alongside epidemiological meta-analyses to dissect the shared molecular pathways activated by these lifestyle factors. A key revelation centers on the modulation of nicotinic acetylcholine receptors (nAChRs), which play a pivotal role in synaptic transmission and neuronal survival. Nicotine, a principal alkaloid in tobacco, is an agonist of these receptors; remarkably, exercise-induced endogenous ligands also modulate nAChR activity, suggesting a common neuroprotective theme.

Delving deeper, the study highlights the role of neuroinflammation—a hallmark of PD pathology—and how both exercise and smoking influence glial cell dynamics. Microglia, the resident immune cells of the brain, when properly regulated, foster an environment conducive to neuronal health. Both exercise and nicotine exposure have been associated with shifts in microglial phenotypes toward an anti-inflammatory profile, reducing the release of neurotoxic cytokines and promoting tissue repair, which may delay neurodegenerative cascades.

Mitochondrial integrity and oxidative stress management emerged as another shared focal point. Exercise enhances mitochondrial biogenesis and efficiency, curbing the production of reactive oxygen species (ROS) that damage cellular components. Nicotine and related compounds may likewise induce moderate mitochondrial adaptation, paradoxically triggering cellular defense mechanisms akin to hormesis. These convergent effects on cellular energetics could underpin the observed epidemiological trends linking both exercise and smoking to lowered PD risk.

Importantly, the study emphasizes precise dosage and timing parameters, recognizing that while exercise is broadly beneficial, nicotine’s toxicity profile necessitates caution. Therapeutic translation calls for innovations in delivering neuroprotective nicotine analogues or mimetics without systemic harm, potentially harnessing the beneficial receptor signaling without the detriments of tobacco.

Genetic factors also modulate individual responsiveness to these protective stimuli. Variants in genes encoding nAChR subunits or mitochondrial maintenance proteins may influence how exercise or nicotine exposure affects neuronal resilience. This awareness opens pathways for personalized medicine approaches in PD prevention or management, tailoring interventions according to genetic makeup to maximize efficacy and safety.

The study’s integrative perspective bridges gaps between disparate fields—neurology, pharmacology, and behavioral science—to propose a unified model wherein disparate stimuli converge on common neuroprotective networks. Such insights could recalibrate public health messaging by disentangling smoking’s toxic effects from isolated neuroprotective pathways, guiding novel drug development that mimics beneficial molecular interactions devoid of harm.

From a technological standpoint, the research employs cutting-edge imaging techniques and bioinformatics to map receptor interactions and downstream signaling cascades in vivo. Continuous advances in neural imaging and wearable technology monitoring exercise parameters may enhance real-time assessment of neuroprotective biomarkers, informing adaptive intervention protocols in high-risk populations.

Despite the promising revelations, the authors caution against misconstruing these findings as an endorsement of smoking. The complexities of tobacco’s systemic impacts far outweigh potential neuroprotective effects, underscoring the imperative for alternative therapeutic channels. Meanwhile, promoting exercise remains an unequivocally safe and accessible strategy to bolster neurological health, with intricate molecular benefits now more clearly understood.

Emerging from this research is a provocative narrative: two lifestyle factors at opposite ends of the health spectrum may unlock similar neuroprotective keys. This duality challenges binary views on health behaviors and advocates for a nuanced understanding of how controlled biochemical stimulation can yield divergent systemic outcomes.

Future research directions proposed include longitudinal clinical trials to validate these mechanistic insights and investigate combinatorial effects of exercise and selective nAChR modulators. Additionally, exploration into other lifestyle or environmental factors that mirror these pathways could expand the repertoire of non-pharmacologic interventions for PD.

In conclusion, the work by Janssen Daalen and colleagues represents a seminal contribution to neurodegenerative research, reframing how exercise and smoking are understood in relation to Parkinson’s disease. By elucidating shared protective mechanisms, this study opens a frontier for innovative therapies and personalized prevention strategies grounded in a sophisticated appreciation of lifestyle influences on brain health.

As Parkinson’s disease continues to impose substantial individual and societal burdens, integrating these dynamic insights into clinical practice and public health frameworks could revolutionize approaches to mitigating neurodegeneration. The convergence of seemingly contradictory factors into a singular neuroprotective paradigm exemplifies the transformative power of modern science to challenge established dogma and inspire hope for impactful medical breakthroughs.

Subject of Research: Neuroprotective mechanisms of exercise and smoking in Parkinson’s disease

Article Title: Exercise and smoking: health rivals revealing shared protective mechanisms in Parkinson’s?

Article References:
Janssen Daalen, J.M., Schootemeijer, S., Oosterhof, T. et al. Exercise and smoking: health rivals revealing shared protective mechanisms in Parkinson’s?
npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01424-6

Image Credits: AI Generated